Pilot Study of an Aerobic Exercise Intervention During Immune Checkpoint Inhibitor Therapy in Early-stage Triple Negative Breast Cancer
To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.
• female and male participants 18 years or older and willing to provide Informed Consent
• clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization))
• Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device
• Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1
• Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel)
• clearance to participate in the study by the patient's medical oncologist
• normal bone marrow function
• able to read/complete study forms/assessments and understand instructions in English